Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 288

1.

Long-term Outcomes and Cost-effectiveness of Breast Cancer Screening with Digital Breast Tomosynthesis in the United States.

Lowry KP, Trentham-Dietz A, Schechter CB, Alagoz O, Barlow WE, Burnside ES, Conant EF, Hampton JM, Huang H, Kerlikowske K, Lee SJ, Miglioretti DL, Sprague BL, Tosteson ANA, Yaffe M, Stout NK.

J Natl Cancer Inst. 2019 Sep 10. pii: djz184. doi: 10.1093/jnci/djz184. [Epub ahead of print]

PMID:
31503283
2.

Patterns of Breast Imaging Use Among Women with a Personal History of Breast Cancer.

Henderson LM, Ichikawa L, Buist DSM, Lee JM, Bush M, Johnson D, Onega T, Nekhlyudov L, Kerlikowske K, Miglioretti DL, Sprague BL, Wernli KJ.

J Gen Intern Med. 2019 Aug 13. doi: 10.1007/s11606-019-05181-6. [Epub ahead of print]

PMID:
31410813
3.

Benefits of Supplemental Ultrasonography With Mammography-Reply.

Lee JM, Smith R, Kerlikowske K.

JAMA Intern Med. 2019 Aug 1;179(8):1150-1151. doi: 10.1001/jamainternmed.2019.2376. No abstract available.

PMID:
31380953
4.

Strategies to Identify Women at High Risk of Advanced Breast Cancer During Routine Screening for Discussion of Supplemental Imaging.

Kerlikowske K, Sprague BL, Tosteson ANA, Wernli KJ, Rauscher GH, Johnson D, Buist DSM, Onega T, Henderson LM, O'Meara ES, Miglioretti DL.

JAMA Intern Med. 2019 Jul 1. doi: 10.1001/jamainternmed.2019.1758. [Epub ahead of print]

PMID:
31260054
5.

Deep learning networks find unique mammographic differences in previous negative mammograms between interval and screen-detected cancers: a case-case study.

Hinton B, Ma L, Mahmoudzadeh AP, Malkov S, Fan B, Greenwood H, Joe B, Lee V, Kerlikowske K, Shepherd J.

Cancer Imaging. 2019 Jun 22;19(1):41. doi: 10.1186/s40644-019-0227-3.

6.

Longitudinal Changes in Volumetric Breast Density in Healthy Women across the Menopausal Transition.

Engmann NJ, Scott C, Jensen MR, Winham SJ, Ma L, Brandt KR, Mahmoudzadeh A, Whaley DH, Hruska CB, Wu FF, Norman AD, Hiatt RA, Heine J, Shepherd J, Pankratz VS, Miglioretti DL, Kerlikowske K, Vachon CM.

Cancer Epidemiol Biomarkers Prev. 2019 Aug;28(8):1324-1330. doi: 10.1158/1055-9965.EPI-18-1375. Epub 2019 Jun 11.

PMID:
31186265
7.

Surveillance Breast MRI and Mammography: Comparison in Women with a Personal History of Breast Cancer.

Wernli KJ, Ichikawa L, Kerlikowske K, Buist DSM, Brandzel SD, Bush M, Johnson D, Henderson LM, Nekhlyudov L, Onega T, Sprague BL, Lee JM, Lehman CD, Miglioretti DL.

Radiology. 2019 Aug;292(2):311-318. doi: 10.1148/radiol.2019182475. Epub 2019 Jun 4.

PMID:
31161975
8.

Discussions of Dense Breasts, Breast Cancer Risk, and Screening Choices in 2019.

Kerlikowske K, Miglioretti DL, Vachon CM.

JAMA. 2019 Jul 2;322(1):69-70. doi: 10.1001/jama.2019.6247. No abstract available.

PMID:
31150040
9.

Combined effect of volumetric breast density and body mass index on breast cancer risk.

Engmann NJ, Scott CG, Jensen MR, Winham S, Miglioretti DL, Ma L, Brandt K, Mahmoudzadeh A, Whaley DH, Hruska C, Wu F, Norman AD, Hiatt RA, Heine J, Shepherd J, Pankratz VS, Vachon CM, Kerlikowske K.

Breast Cancer Res Treat. 2019 Aug;177(1):165-173. doi: 10.1007/s10549-019-05283-z. Epub 2019 May 25.

PMID:
31129803
10.

Body mass index, mammographic density, and breast cancer risk by estrogen receptor subtype.

Shieh Y, Scott CG, Jensen MR, Norman AD, Bertrand KA, Pankratz VS, Brandt KR, Visscher DW, Shepherd JA, Tamimi RM, Vachon CM, Kerlikowske K.

Breast Cancer Res. 2019 Apr 3;21(1):48. doi: 10.1186/s13058-019-1129-9.

11.

Performance of Screening Ultrasonography as an Adjunct to Screening Mammography in Women Across the Spectrum of Breast Cancer Risk.

Lee JM, Arao RF, Sprague BL, Kerlikowske K, Lehman CD, Smith RA, Henderson LM, Rauscher GH, Miglioretti DL.

JAMA Intern Med. 2019 May 1;179(5):658-667. doi: 10.1001/jamainternmed.2018.8372. Erratum in: JAMA Intern Med. 2019 Apr 29;:.

PMID:
30882843
12.

Digital Breast Tomosynthesis: Radiologist Learning Curve.

Miglioretti DL, Abraham L, Lee CI, Buist DSM, Herschorn SD, Sprague BL, Henderson LM, Tosteson ANA, Kerlikowske K; Breast Cancer Surveillance Consortium.

Radiology. 2019 Apr;291(1):34-42. doi: 10.1148/radiol.2019182305. Epub 2019 Feb 26.

PMID:
30806595
13.

Validation of the breast cancer surveillance consortium model of breast cancer risk.

Tice JA, Bissell MCS, Miglioretti DL, Gard CC, Rauscher GH, Dabbous FM, Kerlikowske K.

Breast Cancer Res Treat. 2019 Jun;175(2):519-523. doi: 10.1007/s10549-019-05167-2. Epub 2019 Feb 22.

PMID:
30796654
14.

Re: "Linkage of the ACR National Mammography Database to the Network of State Cancer Registries: Proof of Concept Evaluation by the ACR National Mammography Database Committee".

Miglioretti DL, Lee JM, Kerlikowske K; Breast Cancer Surveillance Consortium.

J Am Coll Radiol. 2019 Feb;16(2):135-136. doi: 10.1016/j.jacr.2018.09.056. No abstract available.

PMID:
30717832
15.

Derived mammographic masking measures based on simulated lesions predict the risk of interval cancer after controlling for known risk factors: a case-case analysis.

Hinton B, Ma L, Mahmoudzadeh AP, Malkov S, Fan B, Greenwood H, Joe B, Lee V, Strand F, Kerlikowske K, Shepherd J.

Med Phys. 2019 Mar;46(3):1309-1316. doi: 10.1002/mp.13410. Epub 2019 Feb 14.

PMID:
30697755
16.

Population-Based Assessment of the Association Between Magnetic Resonance Imaging Background Parenchymal Enhancement and Future Primary Breast Cancer Risk.

Arasu VA, Miglioretti DL, Sprague BL, Alsheik NH, Buist DSM, Henderson LM, Herschorn SD, Lee JM, Onega T, Rauscher GH, Wernli KJ, Lehman CD, Kerlikowske K.

J Clin Oncol. 2019 Apr 20;37(12):954-963. doi: 10.1200/JCO.18.00378. Epub 2019 Jan 9.

PMID:
30625040
17.

Trends in Clinical Breast Density Assessment From the Breast Cancer Surveillance Consortium.

Sprague BL, Kerlikowske K, Bowles EJA, Rauscher GH, Lee CI, Tosteson ANA, Miglioretti DL.

J Natl Cancer Inst. 2019 Jan 8. doi: 10.1093/jnci/djy210. [Epub ahead of print]

PMID:
30624682
18.

Combined Benefit of Quantitative Three-Compartment Breast Image Analysis and Mammography Radiomics in the Classification of Breast Masses in a Clinical Data Set.

Drukker K, Giger ML, Joe BN, Kerlikowske K, Greenwood H, Drukteinis JS, Niell B, Fan B, Malkov S, Avila J, Kazemi L, Shepherd J.

Radiology. 2019 Mar;290(3):621-628. doi: 10.1148/radiol.2018180608. Epub 2018 Dec 11.

PMID:
30526359
19.

Mammography facilities serving vulnerable women have longer follow-up times.

Karliner LS, Kaplan C, Livaudais-Toman J, Kerlikowske K.

Health Serv Res. 2019 Feb;54 Suppl 1:226-233. doi: 10.1111/1475-6773.13083. Epub 2018 Nov 5.

PMID:
30394526
20.

Radiomic Phenotypes of Mammographic Parenchymal Complexity: Toward Augmenting Breast Density in Breast Cancer Risk Assessment.

Kontos D, Winham SJ, Oustimov A, Pantalone L, Hsieh MK, Gastounioti A, Whaley DH, Hruska CB, Kerlikowske K, Brandt K, Conant EF, Vachon CM.

Radiology. 2019 Jan;290(1):41-49. doi: 10.1148/radiol.2018180179. Epub 2018 Oct 30.

PMID:
30375931
21.

The Effect of Digital Breast Tomosynthesis Adoption on Facility-Level Breast Cancer Screening Volume.

Lee CI, Zhu W, Onega TL, Germino J, O'Meara ES, Lehman CD, Henderson LM, Haas JS, Kerlikowske K, Sprague BL, Rauscher GH, Tosteson ANA, Alford-Teaster J, Wernli KJ, Miglioretti DL.

AJR Am J Roentgenol. 2018 Nov;211(5):957-963. doi: 10.2214/AJR.17.19350. Epub 2018 Sep 20.

PMID:
30235000
22.

Cumulative Risk Distribution for Interval Invasive Second Breast Cancers After Negative Surveillance Mammography.

Lee JM, Abraham L, Lam DL, Buist DSM, Kerlikowske K, Miglioretti DL, Houssami N, Lehman CD, Henderson LM, Hubbard RA.

J Clin Oncol. 2018 Jul 10;36(20):2070-2077. doi: 10.1200/JCO.2017.76.8267. Epub 2018 May 2.

23.

Automated and Clinical Breast Imaging Reporting and Data System Density Measures Predict Risk for Screen-Detected and Interval Cancers: A Case-Control Study.

Kerlikowske K, Scott CG, Mahmoudzadeh AP, Ma L, Winham S, Jensen MR, Wu FF, Malkov S, Pankratz VS, Cummings SR, Shepherd JA, Brandt KR, Miglioretti DL, Vachon CM.

Ann Intern Med. 2018 Jun 5;168(11):757-765. doi: 10.7326/M17-3008. Epub 2018 May 1.

24.

Preoperative breast MRI and mortality in older women with breast cancer.

Onega T, Zhu W, Weiss JE, Goodrich M, Tosteson ANA, DeMartini W, Virnig BA, Henderson LM, Buist DSM, Wernli KJ, Kerlikowske K, Hubbard RA.

Breast Cancer Res Treat. 2018 Jul;170(1):149-157. doi: 10.1007/s10549-018-4732-z. Epub 2018 Mar 7.

25.

Does mammographic density mediate risk factor associations with breast cancer? An analysis by tumor characteristics.

Rice MS, Tamimi RM, Bertrand KA, Scott CG, Jensen MR, Norman AD, Visscher DW, Chen YY, Brandt KR, Couch FJ, Shepherd JA, Fan B, Wu FF, Ma L, Collins LC, Cummings SR, Kerlikowske K, Vachon CM.

Breast Cancer Res Treat. 2018 Jul;170(1):129-141. doi: 10.1007/s10549-018-4735-9. Epub 2018 Mar 3.

26.

Family History and Breast Cancer Risk Among Older Women in the Breast Cancer Surveillance Consortium Cohort.

Braithwaite D, Miglioretti DL, Zhu W, Demb J, Trentham-Dietz A, Sprague B, Tice JA, Onega T, Henderson LM, Buist DSM, Ziv E, Walter LC, Kerlikowske K; Breast Cancer Surveillance Consortium.

JAMA Intern Med. 2018 Apr 1;178(4):494-501. doi: 10.1001/jamainternmed.2017.8642.

27.

Breast Biopsy Intensity and Findings Following Breast Cancer Screening in Women With and Without a Personal History of Breast Cancer.

Buist DSM, Abraham L, Lee CI, Lee JM, Lehman C, O'Meara ES, Stout NK, Henderson LM, Hill D, Wernli KJ, Haas JS, Tosteson ANA, Kerlikowske K, Onega T; Breast Cancer Surveillance Consortium.

JAMA Intern Med. 2018 Apr 1;178(4):458-468. doi: 10.1001/jamainternmed.2017.8549.

28.

Preoperative Breast Magnetic Resonance Imaging Use by Breast Density and Family History of Breast Cancer.

Henderson LM, Hubbard RA, Zhu W, Weiss J, Wernli KJ, Goodrich ME, Kerlikowske K, DeMartini W, Ozanne EM, Onega T.

J Womens Health (Larchmt). 2018 Aug;27(8):987-993. doi: 10.1089/jwh.2017.6428. Epub 2018 Jan 15.

29.

Utilization of breast cancer screening with magnetic resonance imaging in community practice.

Hill DA, Haas JS, Wellman R, Hubbard RA, Lee CI, Alford-Teaster J, Wernli KJ, Henderson LM, Stout NK, Tosteson ANA, Kerlikowske K, Onega T.

J Gen Intern Med. 2018 Mar;33(3):275-283. doi: 10.1007/s11606-017-4224-6. Epub 2017 Dec 6.

30.

Relationship between preoperative breast MRI and surgical treatment of non-metastatic breast cancer.

Onega T, Weiss JE, Goodrich ME, Zhu W, DeMartini WB, Kerlikowske K, Ozanne E, Tosteson ANA, Henderson LM, Buist DSM, Wernli KJ, Herschorn SD, Hotaling E, O'Donoghue C, Hubbard R.

J Surg Oncol. 2017 Dec;116(8):1008-1015. doi: 10.1002/jso.24796. Epub 2017 Nov 11.

31.

Effect of Background Parenchymal Enhancement on Breast MR Imaging Interpretive Performance in Community-based Practices.

Ray KM, Kerlikowske K, Lobach IV, Hofmann MB, Greenwood HI, Arasu VA, Hylton NM, Joe BN.

Radiology. 2018 Mar;286(3):822-829. doi: 10.1148/radiol.2017170811. Epub 2017 Oct 25.

32.

Emerging Trends in Family History of Breast Cancer and Associated Risk.

Shiyanbola OO, Arao RF, Miglioretti DL, Sprague BL, Hampton JM, Stout NK, Kerlikowske K, Braithwaite D, Buist DSM, Egan KM, Newcomb PA, Trentham-Dietz A.

Cancer Epidemiol Biomarkers Prev. 2017 Dec;26(12):1753-1760. doi: 10.1158/1055-9965.EPI-17-0531. Epub 2017 Oct 6.

33.

Combining quantitative and qualitative breast density measures to assess breast cancer risk.

Kerlikowske K, Ma L, Scott CG, Mahmoudzadeh AP, Jensen MR, Sprague BL, Henderson LM, Pankratz VS, Cummings SR, Miglioretti DL, Vachon CM, Shepherd JA.

Breast Cancer Res. 2017 Aug 22;19(1):97. doi: 10.1186/s13058-017-0887-5.

34.

Joint relative risks for estrogen receptor-positive breast cancer from a clinical model, polygenic risk score, and sex hormones.

Shieh Y, Hu D, Ma L, Huntsman S, Gard CC, Leung JWT, Tice JA, Ziv E, Kerlikowske K, Cummings SR.

Breast Cancer Res Treat. 2017 Nov;166(2):603-612. doi: 10.1007/s10549-017-4430-2. Epub 2017 Aug 8.

35.

Women's Awareness and Perceived Importance of the Harms and Benefits of Mammography Screening: Results From a 2016 National Survey.

Yu J, Nagler RH, Fowler EF, Kerlikowske K, Gollust SE.

JAMA Intern Med. 2017 Sep 1;177(9):1381-1382. doi: 10.1001/jamainternmed.2017.2247. No abstract available.

36.

Interaction of mammographic breast density with menopausal status and postmenopausal hormone use in relation to the risk of aggressive breast cancer subtypes.

Yaghjyan L, Tamimi RM, Bertrand KA, Scott CG, Jensen MR, Pankratz VS, Brandt K, Visscher D, Norman A, Couch F, Shepherd J, Fan B, Chen YY, Ma L, Beck AH, Cummings SR, Kerlikowske K, Vachon CM.

Breast Cancer Res Treat. 2017 Sep;165(2):421-431. doi: 10.1007/s10549-017-4341-2. Epub 2017 Jun 17.

37.

Disparities in abnormal mammogram follow-up time for Asian women compared with non-Hispanic white women and between Asian ethnic groups.

Nguyen KH, Pasick RJ, Stewart SL, Kerlikowske K, Karliner LS.

Cancer. 2017 Sep 15;123(18):3468-3475. doi: 10.1002/cncr.30756. Epub 2017 Jun 12.

38.

Performance Benchmarks for Screening Breast MR Imaging in Community Practice.

Lee JM, Ichikawa L, Valencia E, Miglioretti DL, Wernli K, Buist DSM, Kerlikowske K, Henderson LM, Sprague BL, Onega T, Rauscher GH, Lehman CD.

Radiology. 2017 Oct;285(1):44-52. doi: 10.1148/radiol.2017162033. Epub 2017 Jun 5.

39.

Correlation Between Screening Mammography Interpretive Performance on a Test Set and Performance in Clinical Practice.

Miglioretti DL, Ichikawa L, Smith RA, Buist DSM, Carney PA, Geller B, Monsees B, Onega T, Rosenberg R, Sickles EA, Yankaskas BC, Kerlikowske K.

Acad Radiol. 2017 Oct;24(10):1256-1264. doi: 10.1016/j.acra.2017.03.016. Epub 2017 May 24.

40.

National Performance Benchmarks for Modern Diagnostic Digital Mammography: Update from the Breast Cancer Surveillance Consortium.

Sprague BL, Arao RF, Miglioretti DL, Henderson LM, Buist DS, Onega T, Rauscher GH, Lee JM, Tosteson AN, Kerlikowske K, Lehman CD; Breast Cancer Surveillance Consortium.

Radiology. 2017 Apr;283(1):59-69. doi: 10.1148/radiol.2017161519. Epub 2017 Feb 28.

41.

Supplemental Breast Cancer Screening: A Density Conundrum.

Tice JA, Kerlikowske K.

J Gen Intern Med. 2017 Jun;32(6):593-594. doi: 10.1007/s11606-017-3989-y. No abstract available.

42.

Women's experiences and preferences regarding breast imaging after completing breast cancer treatment.

Brandzel S, Rosenberg DE, Johnson D, Bush M, Kerlikowske K, Onega T, Henderson L, Nekhlyudov L, DeMartini W, Wernli KJ.

Patient Prefer Adherence. 2017 Feb 1;11:199-204. doi: 10.2147/PPA.S122244. eCollection 2017.

43.

Population-Attributable Risk Proportion of Clinical Risk Factors for Breast Cancer.

Engmann NJ, Golmakani MK, Miglioretti DL, Sprague BL, Kerlikowske K; Breast Cancer Surveillance Consortium.

JAMA Oncol. 2017 Sep 1;3(9):1228-1236. doi: 10.1001/jamaoncol.2016.6326.

44.

Longitudinal Changes in Volumetric Breast Density with Tamoxifen and Aromatase Inhibitors.

Engmann NJ, Scott CG, Jensen MR, Ma L, Brandt KR, Mahmoudzadeh AP, Malkov S, Whaley DH, Hruska CB, Wu FF, Winham SJ, Miglioretti DL, Norman AD, Heine JJ, Shepherd J, Pankratz VS, Vachon CM, Kerlikowske K.

Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):930-937. doi: 10.1158/1055-9965.EPI-16-0882. Epub 2017 Feb 1.

45.

Using Breast Cancer Risk Associated Polymorphisms to Identify Women for Breast Cancer Chemoprevention.

Ziv E, Tice JA, Sprague B, Vachon CM, Cummings SR, Kerlikowske K.

PLoS One. 2017 Jan 20;12(1):e0168601. doi: 10.1371/journal.pone.0168601. eCollection 2017.

46.

Family History of Breast Cancer, Breast Density, and Breast Cancer Risk in a U.S. Breast Cancer Screening Population.

Ahern TP, Sprague BL, Bissell MCS, Miglioretti DL, Buist DSM, Braithwaite D, Kerlikowske K.

Cancer Epidemiol Biomarkers Prev. 2017 Jun;26(6):938-944. doi: 10.1158/1055-9965.EPI-16-0801. Epub 2017 Jan 17.

47.

Erratum to: Mammographic texture and risk of breast cancer by tumor type and estrogen receptor status.

Malkov S, Shepherd JA, Scott CG, Tamimi RM, Ma L, Bertrand KA, Couch F, Jensen MR, Mahmoudzadeh AP, Fan B, Norman A, Brandt KR, Pankratz VS, Vachon CM, Kerlikowske K.

Breast Cancer Res. 2017 Jan 4;19(1):1. doi: 10.1186/s13058-016-0797-y. No abstract available.

48.

Risk Factors That Increase Risk of Estrogen Receptor-Positive and -Negative Breast Cancer.

Kerlikowske K, Gard CC, Tice JA, Ziv E, Cummings SR, Miglioretti DL; Breast Cancer Surveillance Consortium.

J Natl Cancer Inst. 2016 Dec 31;109(5). doi: 10.1093/jnci/djw276. Print 2017 May.

49.

Mammographic texture and risk of breast cancer by tumor type and estrogen receptor status.

Malkov S, Shepherd JA, Scott CG, Tamimi RM, Ma L, Bertrand KA, Couch F, Jensen MR, Mahmoudzadeh AP, Fan B, Norman A, Brandt KR, Pankratz VS, Vachon CM, Kerlikowske K.

Breast Cancer Res. 2016 Dec 6;18(1):122. Erratum in: Breast Cancer Res. 2017 Jan 4;19(1):1.

50.

National Performance Benchmarks for Modern Screening Digital Mammography: Update from the Breast Cancer Surveillance Consortium.

Lehman CD, Arao RF, Sprague BL, Lee JM, Buist DS, Kerlikowske K, Henderson LM, Onega T, Tosteson AN, Rauscher GH, Miglioretti DL.

Radiology. 2017 Apr;283(1):49-58. doi: 10.1148/radiol.2016161174. Epub 2016 Dec 5.

Supplemental Content

Loading ...
Support Center